Overview

Initiative to Minimize Disparities in Postoperative Prostate Cancer Care

Status:
Not yet recruiting
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
Einstein Healthcare Network in North Philadelphia serves a predominantly underserved medical community. The investigators routinely see patients who cannot afford PDE-5 inhibitors and absorbent pads after prostate surgery, which help with sexual rehabilitation after surgery and reduced quality of life secondary to urinary incontinence after surgery, respectively. The goal of our study is to provide PDE-5 inhibitors and absorbent pads to patients who would be unable to afford them. We hypothesize that providing PDE-5 inhibitor (Tadalafil 4mg taken every other day for 6 months) and absorbent pads for 6 months will result in improved sexual health and management of urinary incontinence after radical prostatectomy.
Phase:
Phase 4
Details
Lead Sponsor:
Albert Einstein Healthcare Network
Treatments:
Tadalafil